Compass Pathways Azione

Compass Pathways CAGR FCF 3A

Il Crescita FCL CAGR (3 Anni) di Compass Pathways (CMPS) al 8 ago 2026 è 14,03 %.

CAGR FCF 3A

14,03 %

Ultimo aggiornamento:

Crescita FCL CAGR (3 Anni) di Compass Pathways ammonta a 2026 14,03 % . Crescita FCL CAGR (3 Anni) di Compass Pathways ammontava a 2025 0,00 . Diminuisce del % superiore rispetto all'anno precedente.
Access this data via the Eulerpool API

Compass Pathways Analisi delle Azioni

Cosa fa Compass Pathways? Compass Pathways PLC is a leading company specializing in the development of groundbreaking therapies for the treatment of mental illnesses. The company was founded in 2016 and is headquartered in London. Its goal is to revolutionize the treatment of depression and other mental illnesses. The business model of Compass Pathways is based on researching psychedelics as a potential treatment for patients suffering from severe depression and anxiety disorders. The company uses innovative approaches to precisely study the effects of psychedelics on the human brain and develop new therapy concepts and products from that. An important area of Compass Pathways is clinical research. The company collaborates closely with leading research institutions to understand the impacts of psychedelics on the human brain. The research results are then used to develop innovative methods for therapeutic use of psychedelics. Another important area of Compass Pathways is the development of therapeutic products. The company has developed a patented process for producing psilocybin, a substance found in hallucinogenic mushrooms. This process achieves a very high purity of the substance, enabling precise dosing and better control of its effects. The flagship product of Compass Pathways is COMP360, a medication based on psilocybin that is being developed for the treatment of depression. The medication is currently in clinical Phase 2 trials, showing promising results. If COMP360 receives approval, it has the potential to drastically change the way we treat depression. Compass Pathways is also active in other areas. The company conducts a range of research projects related to various psychedelic substances, including LSD and other hallucinogens. Another important area of Compass Pathways is training therapists and other professionals in the use of psychedelic substances. The company offers relevant courses to promote understanding of the therapeutic use of psychedelics and enable their safe and effective application for patient treatment. Overall, Compass Pathways is a company focused on the development of groundbreaking therapies for mental illnesses. Through combining cutting-edge research, innovative products, and professional education, the company has the potential to revolutionize the way we treat mental illnesses. Compass Pathways è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Compass Pathways azioni

Crescita FCL CAGR (3 Anni) di Compass Pathways è 14,03 % nel 2026.

Su Eulerpool è possibile consultare lo sviluppo storico completo del Compass Pathways di Crescita FCL CAGR (3 Anni) dal 2006, con valori annuali, grafici e analisi dettagliate.

Il CAGR del FCL a 3 anni mostra il tasso di crescita annuale composto del flusso di cassa libero su tre anni.

Per valutare di Crescita FCL CAGR (3 Anni), è essenziale confrontarlo con i competitor nello stesso settore e industria. Su Eulerpool puoi trovare confronti diretti con l'industria per Crescita FCL CAGR (3 Anni).

Il di Crescita FCL CAGR (3 Anni) è un fattore chiave per gli investitori. I cambiamenti in questa metrica possono segnalare il miglioramento o il deterioramento dei fondamentali, impattando direttamente il prezzo delle azioni. Su Eulerpool puoi tracciare il Compass Pathways di Crescita FCL CAGR (3 Anni) storicamente e in tempo reale.

Access this data via the Eulerpool API

Crescita — Compass Pathways

Tutte le Metriche Finanziarie — Compass Pathways